Top MarketRank™ StocksTop MarketRank™Most-Downgraded StocksMost-DowngradedNASDAQ:DXCM DexCom (DXCM) Stock Price, News & Analysis $71.92 +2.46 (+3.54%) (As of 09/19/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About DexCom Stock (NASDAQ:DXCM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$70.27▼$72.3450-Day Range$64.00▼$116.0652-Week Range$62.34▼$142.00Volume4.18 million shsAverage Volume3.79 million shsMarket Capitalization$28.60 billionP/E Ratio46.40Dividend YieldN/APrice Target$112.25Consensus RatingModerate Buy Company OverviewDexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.Read More… Trump’s weapon lurks in abandoned America (Ad)Unemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…Go here now to watch my new documentary DexCom Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 100th PercentileDexCom scored higher than 100% of companies evaluated by MarketBeat, and ranked 5th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingDexCom has received a consensus rating of Moderate Buy. The company's average rating score is 2.72, and is based on 11 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageDexCom has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about DexCom's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth18.93% Earnings GrowthEarnings for DexCom are expected to grow by 18.93% in the coming year, from $1.69 to $2.01 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DexCom is 46.40, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 131.01.Price to Earnings Ratio vs. SectorThe P/E ratio of DexCom is 46.40, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 118.08.Price to Earnings Growth RatioDexCom has a PEG Ratio of 2.12. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDexCom has a P/B Ratio of 13.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about DexCom's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.84% of the outstanding shares of DexCom have been sold short.Short Interest Ratio / Days to CoverDexCom has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DexCom has recently decreased by 3.04%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDexCom does not currently pay a dividend.Dividend GrowthDexCom does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.76 Percentage of Shares Shorted1.84% of the outstanding shares of DexCom have been sold short.Short Interest Ratio / Days to CoverDexCom has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DexCom has recently decreased by 3.04%, indicating that investor sentiment is improving. News and Social Media1.7 / 5News Sentiment0.14 News SentimentDexCom has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 44 news articles for DexCom this week, compared to 17 articles on an average week.Search InterestOnly 34 people have searched for DXCM on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $201,708.00 in company stock.Percentage Held by InsidersOnly 0.30% of the stock of DexCom is held by insiders.Percentage Held by Institutions97.75% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about DexCom's insider trading history. DXCM Stock News HeadlinesInsider Selling: DexCom, Inc. (NASDAQ:DXCM) EVP Sells 426 Shares of StockSeptember 12, 2024 | insidertrades.comDexCom, Inc. (NASDAQ:DXCM) COO Sells $51,585.90 in StockSeptember 12, 2024 | insidertrades.comWhy You Should NOT Trade This MarketYou'll be interested in our 5-Day Options Trading Challenge, starting September 23. So, what makes this different from every other options research you may have seen? Well, for starters... most of them want you to first BUY their service... which is usually thousands of dollars...September 19, 2024 | InvestorPlace (Ad)Lost Money on DexCom, Inc. (DXCM)? Join Class Action Suit Seeking Recovery – Contact Levi & KorsinskySeptember 19 at 1:33 PM | globenewswire.comDexCom (DXCM) Blamed Disruptive Sales Force Changes For Its Disappointing Q2 2024 Results And Outlook, Resulting In 40% Stock Drop And Class Action - Hagens BermanSeptember 19 at 1:06 PM | globenewswire.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DexComSeptember 19 at 11:20 AM | globenewswire.comDXCM INVESTOR UPDATE: Suffer Losses on Your DexCom, Inc. Investment? Contact BFA Law by October 21 about Pending Class Action Lawsuit (Nasdaq:DXCM)September 19 at 7:11 AM | globenewswire.comThe Gross Law Firm Notifies Shareholders of DexCom, Inc.(DXCM) of a Class Action Lawsuit and an Upcoming DeadlineSeptember 19 at 5:45 AM | prnewswire.comSee More Headlines DXCM Stock Analysis - Frequently Asked Questions How have DXCM shares performed this year? DexCom's stock was trading at $124.09 at the beginning of the year. Since then, DXCM shares have decreased by 42.0% and is now trading at $71.92. View the best growth stocks for 2024 here. How were DexCom's earnings last quarter? DexCom, Inc. (NASDAQ:DXCM) posted its quarterly earnings results on Thursday, July, 25th. The medical device company reported $0.43 earnings per share for the quarter, topping analysts' consensus estimates of $0.39 by $0.04. The business's quarterly revenue was up 15.3% on a year-over-year basis. Read the conference call transcript. When did DexCom's stock split? Shares of DexCom split before market open on Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly created shares were distributed to shareholders after the closing bell on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. Does DexCom have any subsidiaries? DexCom subsidiaries include these companies: TypeZero Technologies Inc, Nintamed Handels GmbH, DexCapital LLC, DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom (Canada) Inc., DexCom Deutschland GmbH, and more. Who are DexCom's major shareholders? DexCom's top institutional shareholders include Baillie Gifford & Co. (3.85%), Legal & General Group Plc (0.75%), Massachusetts Financial Services Co. MA (0.61%) and Vaughan Nelson Investment Management L.P. (0.41%). Insiders that own company stock include Kevin R Sayer, Jacob Steven Leach, Steven Robert Pacelli, Jereme M Sylvain, Sadie Stern, Michael Jon Brown, Barry J Regan, Steven R Altman, Paul R Flynn, Shelly Ramasamy Selvaraj, Matthew Vincent Dolan, Bridgette P Heller, Chad Patterson, Barbara Kahn, Richard Alexander Collins, Mark G Foletta and Nicholas Augustinos. View institutional ownership trends. How do I buy shares of DexCom? Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of DexCom own? Based on aggregate information from My MarketBeat watchlists, some other companies that DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM) and ServiceNow (NOW). Company Calendar Last Earnings7/25/2024Today9/19/2024Next Earnings (Estimated)10/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Devices Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:DXCM CUSIP25213110 CIK1093557 Webwww.dexcom.com Phone(858) 200-0200Fax858-200-0201Employees9,500Year Founded1999Price Target and Rating Average Stock Price Target$112.25 High Stock Price Target$161.00 Low Stock Price Target$75.00 Potential Upside/Downside+56.1%Consensus RatingModerate Buy Rating Score (0-4)2.72 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)$1.55 Trailing P/E Ratio46.40 Forward P/E Ratio42.56 P/E Growth2.12Net Income$541.50 million Net Margins16.95% Pretax Margin20.51% Return on Equity31.41% Return on Assets10.84% Debt Debt-to-Equity Ratio1.00 Current Ratio2.82 Quick Ratio2.48 Sales & Book Value Annual Sales$3.93 billion Price / Sales7.27 Cash Flow$2.17 per share Price / Cash Flow33.09 Book Value$5.35 per share Price / Book13.44Miscellaneous Outstanding Shares397,684,000Free Float396,491,000Market Cap$28.60 billion OptionableOptionable Beta1.18 Social Links Should I Buy DexCom Stock? DXCM Pros and Cons Explained These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 4, 2024. Please send any questions or comments about these DexCom pros and cons to contact@marketbeat.com. DexCom Bull Case Here are some ways that investors could benefit from investing in DexCom, Inc.: DexCom, Inc. is a medical device company that focuses on continuous glucose monitoring (CGM) systems, a growing market due to the increasing prevalence of diabetes worldwide. DexCom Bear Case Investors should be bearish about investing in DexCom, Inc. for these reasons: Current stock price of DexCom, Inc. may be overvalued based on recent market trends and financial analysis. This page (NASDAQ:DXCM) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding DexCom, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share DexCom With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.